Pharmaceutical - Pharmaceutical, Abilify Maintena

Filter

Popular Filters

Abilify Maintena cuts hospitalization rates for patients with schizophrenia vs oral antipsychotics

07-04-2014

Danish CNS drug specialist Lundbeck and partner Japanese drugmaker Otsuka Pharmaceutical today announced…

Abilify MaintenaLundbeckNeurologicalOtsukaPharmaceuticalResearch

Lundbeck and Otsuka update on European launch of Abilify Maintena

Lundbeck and Otsuka update on European launch of Abilify Maintena

17-03-2014

Danish CNS drug specialist Lundbeck and Japanese drugmaker Otsuka Pharmaceutical’s European subsidiary…

Abilify MaintenaEuropeLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceutical

New schizophrenia drug Abilify to lead the market by 2016

New schizophrenia drug Abilify to lead the market by 2016

29-12-2013

Long-acting depot therapy Abilify Maintena (aripiprazole) will become the leading injectable schizophrenia…

AbilifyAbilify MaintenaFinancialGlobalLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceutical

Otsuka and Lundbeck’s schizophrenia drug Abilify Maintena approved in EU

Otsuka and Lundbeck’s schizophrenia drug Abilify Maintena approved in EU

21-11-2013

Japan’s Otsuka Pharmaceutical (TYO: 4768) and partner Lundbeck (LUN: CO) have received approval from…

Abilify MaintenaAsia-PacificEuropeLundbeckNeurologicalOtsukaPharmaceuticalRegulation

Roche/Chugai's bitopertin set to garner $1.5 billion sales in 2022

23-08-2013

Swiss drug major Roche (ROG: SIX) and its majority-owned Japanese affiliate Chugai's glycine transporter-1…

AbilifyAbilify MaintenabitopertinChugai PharmaceuticalEuropeGenericsJanssenLundbeckMarkets & MarketingNeurologicalNorth AmericaOtsukaPaliperidonePharmaceuticalRocheSeroquelZyprexa

Positive trial results for Otsuka and Lundbeck's Abilify Maintena in schizophrenia

22-05-2013

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578)) and Denmark's Lundbeck (LUND: DC) today (May 22)…

Abilify MaintenaLundbeckNeurologicalOtsukaPharmaceuticalResearch

Otsuka and Lundbeck expand current Abilify collaboration

07-03-2013

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578) and Denmark-based CNS specialist Lundbeck (LUND:…

AbilifyAbilify MaintenabrexpiprazoleEuropeLicensingLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceutical

FDA approves Otsuka and Lundbeck's once-monthly Abilify Maintena for schizophrenia

01-03-2013

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578) and Danish partner Lundbeck (LUND: DC) have received…

Abilify MaintenaAlkermesLundbeckNeurologicalNorth AmericaOtsukaPharmaceuticalRegulation

Parexel

Parexel

Back to top